

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

SEP 18 2006

George W. Johnston Hoffman-La Roche Inc. Patent Law Department 340 Kingsland Street Nutley, New Jersey 07110 In Re: Patent Term Extension Application for U.S. Patent No. 6,083,953

Dear Mr. Johnston:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 6,083,953 for a period of 244 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: http://www.fda.gov/opacom/morechoices/fdaforms/default.html (http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571), 272-7755, or by e-mail at mary till@uspto.gov.

Mary C. Till (Legal Advisor

Office of Patent Legal Administration Office of the Deputy Commissioner for Patent Examination Policy

cc:

Office of Regulatory Policy

HFD-7

5600 Fishers Lane (Rockwall II Rm 1101)

Rockville, MD 20857

Attention: Beverly Friedman

RE: VALCYTE® (valganciclovir HCl)

FDA Docket No.: 01E-0403

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

(68) PATENT NO. : 6,083,953

(45) ISSUED : July 4, 2000

(75) INVENTOR : John Joseph Nestor, et al.

(73) PATENT OWNER : Roche Palo Alto LLC

(95) PRODUCT : VALCYTE® (valganciclovir HCl)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 6,083,953 based upon the regulatory review of the product VALCYTE® (valganciclovir HCl) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 244 days

from July 28, 2014, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).

I have caused the seal of the United States Patent and Trademark Office to be affixed this 14th day of September 2006.

Jon W. Dudas

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office